A cute myeloid leukemia (AML) is an aggressive malignancy of the hematopoietic system associated with a relatively poor outcome, which has not improved significantly for the past three decades, with long-term overall survival rates for younger patients ranging from 40%-50%. 1 Recently, high-throughput sequencing technology and DNA methylation profiling helped to characterize the genomic and epigenomic landscape of this disease. The process of leukemic transformation is driven by a series of somatically acquired mutations and chromosomal aberrations, which appear to determine many of the biological and clinical aspects of the disease at presentation. 2 Chromosomal abnormalities detected through conventional cytogenetics are present in more than half of adult AML samples 3, 4 and somatically acquired recurrent mutations have been identified in a number of genes, including NPM1, FLT3, CEBPA, MLL, NRAS, WT1, KIT, RUNX1, TET2, IDH1, IDH2, and others. 5 Similar to many (but not all) other human malignancies, many cases of AML display evidence of a "hierarchical" cellular organization, with a minor fraction of self-renewing cancer stem cells (CSCs) at the apex of this hierarchy that maintain the disease. CSCs are defined as cells that are capable of re-initiating the disease if transplanted into immunodeficient animals and differentiating into all the cells comprising the malignancy. The earliest conceptual idea of leukemia being organized in a hierarchical manner traces back to studies performed to identify clonogenic AML progenitors in vitro. 6, 7 Dick and colleagues later demonstrated that AML is organized in this hierarchical fashion in vivo, similar to normal hematopoiesis, and is therefore replenished by leukemia stem cells (LSCs). [8] [9] [10] From a clinical perspective, the cancer stem cell model implies that in order to eradicate the disease and achieve long-term cure for patients, the treatment also has to eliminate the LSC population. As a neoplastic cellular reservoir that likely contributes to chemotherapy resistance, subclone generation, persistent residual disease, and eventual relapse, LSCs are an attractive target for the development of new antileukemic therapies. Their properties of relative quiescence, resistance to apoptosis, self-renewal, and increased drug efflux mandate a modified approach from that of conventional therapies aimed at the bulk, rapidly dividing disease. In this review, we aim to review emerging therapeutics specifically targeting AML-LSCs including biological and small molecule therapeutics, as well as hematopoietic niche-related therapy approaches.
DETECTION OF AML STEM AND PROGENITOR CELLS
In the original studies using fluorescence-activated cell sorting (FACS) from a variety of AML subtypes, LSC were shown to be negative for expression of lineage markers (Lin À ), positive for expression of CD34, and negative for expression of CD38 as demonstrated by engraftment in NOD/SCID mice [10] and long-term culture-initiating activity in vitro. 11, 12 Further work by the Dick laboratory and others, 13, 14 using both intrafemoral and intravenous tail-vein injection and a more permissive NOD/SCID/ interleukin 2 receptor gamma null (NSG) mouse model, has shown that in virtually all cases leukemia-initiating cells reside in the CD34
À fraction. 15 In at least half of the samples, LSCs are also present in at least one other fraction (usually the CD34 þ /CD38 þ fraction and sometimes in the CD34 À fraction), although a fraction devoid of leukemia-initiating activity always exists but cannot be identified based on current methods. 15 Furthermore, in certain genetically defined cases such as AML with mutation in nucleophosmin 1 (NPM1c), LSCs have been found predominantly within the CD34 À fraction in half of the cases. 16 More recently, CD34 þ LSC populations have been further refined to show the coexistence of two distinct LSC populations studied in patients with CD34
þ AML (which is detectable on the bulk population in the majority of cases). 17 These two populations resemble normal lymphoid-primed multi-potent progenitors (LMPP-like
and are consistent with a progenitor acquiring self-renewal properties rather than a direct HSC origin for AML. 17 Further improvements of LSC detection using more sensitive methods such as humanized microenvironments 18 and integration of genetic mutation data are required to find superior immunophenotypic markers for LSCs.
Separation of leukemic cells based on drug efflux (socalled "side" population cells, which exclude Hoeschst stain via adenosine triphosphate [ATP]-binding cassette transporter G2) 19, 20 and high aldehyde dehydrogenase 1 activity (using a cell-permeable fluorescent substrate) 21 has also been demonstrated to enrich for leukemia-initiating activity, analogous to studies with normal hematopoietic cells.
DETECTION OF PRE-LEUKEMIC STEM CELLS
Gene expression profiling identified TIM3, a cellsurface mucin domain-containing molecule, upregulated at the mRNA and protein level in CD34
À HSCs. 22 This was found to be an informative flow cytometry marker to prospectively separate residual HSCs from leukemic cells (including LSCs) in blood and bone marrow samples at the time of diagnosis. DNA sequencing of these residual HSCs has found that many patients harbor a high proportion of mutated "pre-leukemic" stem cells bearing some, but not all, of the mutations present in the bulk AML. These residual HSCs can give rise to normal lymphoid and myeloid engraftment when transplanted into NSG mice. Similar to colon cancer, the discovery of pre-leukemic HSCs supports a stepwise progression in the clonal evolution of AML and suggests that relapse could possibly occur not only from leukemic clonal or subclonal outgrowth but also from further evolution of pre-leukemic mutated clones. 23 Many of the mutations found in Lin
À HSCs are in epigenetic modifiers such TET2, DNMT3A, and IDH1/2, rather than proliferative mutations, underscoring a role for epigenetic dysregulation in establishing a pro-leukemogenic state. 24 Recently, the existence of clonal hematopoiesis carrying the same mutations was confirmed in two large cohort studies performed in elderly individuals with no hematologic malignancies. 25, 26 CLINICAL OUTCOME AND MINIMAL RESIDUAL DISEASE
The number of LSCs in a patient's bone marrow, either defined immunophenotypically or by xenograft transplantation, correlates strongly with both prognosis and ultimate clinical outcome. A high proportion of CD34 þ / CD38
À cells at the time of AML diagnosis is associated with LSC engraftment in NOD/SCID mice, high minimal residual disease after chemotherapy, and poor patient survival. 27 Similarly, ALDH-bright cells in primary samples correlated with leukemic blast persistence after induction chemotherapy and adverse outcome. 28 In addition, patients whose leukemic cells are able to initiate leukemia in the NOD/SCID assay had a significant shorter overall survival than those with leukemia cells that did not engraft, indicating that standard leukemiainitiating cell assays have prognostic meaning. 29 More recently, a detailed study of CD34 þ subcompartments in patients receiving epigenetic therapies azacitidine and sodium valproate showed persistence of LMPP and GMP-like LSCs even in patients that achieved a complete remission (CR), highlighting the need for more effective therapy active against LSCs. 30 
BIOLOGICAL THERAPIES TARGETING LSC
To date, a major focus of research has been the identification of cell surface markers that are differentially upregulated on LSCs but not on normal human HSCs in the majority of patients. These have been difficult to identify, and thus far no one unique marker has been discovered that is universally expressed on CD34 þ /CD38 Majeti, 2011 39 ). Translation to the clinic has progressed rapidly for a humanized monoclonal IgG2 antibody (CSL360) that binds the interleukin-3 receptor alpha chain (CD123) with high affinity and blocks interleukin-3-mediated survival and proliferation of LSCs. In a phase I trial of relapsed AML, intravenous administration of CSL360 was demonstrated to be safe with clinical responses obtained in two of 16 patients as monotherapy. An engineered version with superior natural killer (NK) cell CD16 Fc-mediated binding affinity (CSL362) is now in phase I/II trial. 40 The inhibitory SIRPα ligand, CD47, was found to be upregulated in LSCs compared to normal HSCs by gene expression profiling. 33 CD47 is ubiquitously expressed on all tissues, including red blood cells comprising a negative signal to prevent homeostatic phagocytosis, and its increased expression on LSCs likely reflects one of several innate immune escape mechanisms used by CSC. Clinical development of CD47-blocking monoclonal antibodies and engineered highaffinity SIRPα variants is currently in progress.
While the myeloid marker CD33 is expressed at low levels on CD34 þ /CD38 À LSCs as originally defined, its expression can be found in many subpopulations that have demonstrated leukemia-initiating activity making it a potential target. Multiple clinical trials with gemtuzumab ozogamicin, an anti-CD33 monoclonal antibody conjugated to chalicheamicin, which was removed from the market due to toxicity, have demonstrated increased remission in combination with chemotherapy in young adults 41 but whether it has a major role in eradicating LSCs has not been shown. A new antibody drug conjugate, SGN-CD33A, engineered to have more predictable pharmacokinetics and drug delivery with a better toxicity profile is currently under clinical investigation. 42 
TARGETING OF LSCS USING SMALL MOLECULE AGENTS
Ever since the discovery of LSCs in AML, there has been a tremendous amount of interest in the development of therapies that exploit the inherent biological differences between LSCs and normal HSPCs. In contrast to antibody-based therapies as discussed in the previous section, therapies based on small molecule agents have the ability to target intracellular proteins and pathways. These therapies act by inhibiting signaling pathways (eg, nuclear factor-κB [NF-κB]) or cellular functions (eg, oxidative phosphorylation) that are uniquely required for LSC survival and/or maintenance. Other therapies act by inducing stresses (eg, oxidative stress) that preferentially compromise LSC activity. Many of the agents have pleiotropic effects. Here, we present a comprehensive list of small-molecule agents that have previously been reported to have anti-LSC activity ( Table 2 ) and focus our discussion on some of the most promising approaches.
Inhibition of NF-κB
NF-κB is a dimeric transcription factor complex that controls the expression of a vast number of genes in cellular responses to stimuli. 43 In the unstimulated state, the complex is sequestered in the cytoplasm by a family of inhibitors, called IκBs. 43 Guzman et al initially reported that NF-κB is constitutively active in AML cells enriched for LSCs (defined immunophenotypically as CD34
as determined by electrophoretic mobility shift assay (EMSA) and gene expression analysis. 44 In contrast, NF-κB activity was not detectable in unstimulated normal CD34 þ HSPCs. Treatment of primary AML samples with the proteasome inhibitor MG-132, which inhibits NF-κB activity by preventing degradation of IκBα, resulted in rapid induction of cell death in AML LSCs but not normal CD34 þ HSPCs, providing evidence for the importance of NF-κB signaling in supporting LSC survival.
The underlying basis for constitutive NF-κB activity in AML cells is likely due to aberrant FLT3, RAS, and/or AKT/PI3K signaling, which are known to induce strong activation of the NF-κB pathway. 45, 46 Autocrine tumor necrosis factor (TNF)α secretion has also been shown to promote constitutive NF-κB activation. 47 Transforming growth factor-β-activated kinase 1 (TAK1) that forms a kinase complex required for NF-κB activation was recently found to be upregulated in CD34
þ AML cells compared with CD34
þ normal bone marrow cells, providing another potential mechanism for upregulation of NF-κB activity in LSCs. 48 In addition to proteasome inhibitors like MG-132, other compounds with inhibitory activity against NF-κB, including parthenolide (PTL), 49 AR-42, 50 and niclosamide, 51 have also been reported to target primitive AML cells. PTL is the major active compound in the herbal medicine Feverfew (Tanacetum parthenium) and is one of the first compounds shown to selectively ablate LSCs without significant toxicity to normal HSPCs. 49, 52 Treatment of primary AML samples ex vivo with PTL preferentially reduced the viability of CD34 AML cells and their engraftment potential in NOD/SCID mice. 49, 52 Although PTL clearly inhibits the activity of NF-κB, it also increases the level of reactive oxygen species (ROS) and activates p53 signaling. These processes contribute to the induction of apoptosis in LSCs along with NF-κB inactivation. 49, 52 Indeed, expression of a degradation-resistant form of IκBα, which specifically downregulates NF-κB activity, was found to be insufficient for the rapid and extensive apoptosis of LSCs seen with PTL. 53 Thus, NF-κB inhibitors will most likely be used in combination with conventional chemotherapeutic or other novel targeted agents to achieve a synergistic effect. Potential agents include JNK inhibitors, 54 histone deacetylase (HDAC) inhibitors, 55 and idarubicin, 53 which have all been shown to synergize with NF-κB inhibition to eliminate primitive AML cells.
Inhibition of BET Family Proteins
Changes in the epigenetic landscape are thought to play a critical role in AML leukemogenesis as supported by the high frequency of mutations in genes (eg, TET2, DNMT3A, MLL) that affect DNA methylation and histone modifications. 5 Recent evidence suggests that these mutations contribute to development of leukemia by blocking differentiation and increasing self-renewal. 56, 57 Reversal of these epigenetic changes can potentially deplete LSCs by promoting terminal myeloid differentiation. In order to determine specific dependencies on chromatin regulators in a genetically defined mouse model of AML (MLL-AF9/ Nras G12D ), Zuber et al performed an unbiased RNA interference screen using a custom library of small hairpin RNAs targeting known chromatin regulators. 58 The screen identified bromodomain-containing 4 (BRD4), which is a member of the BET (bromodomain and extra terminal domain) family that recognizes acetylated histones, to be required for disease maintenance. 58, 59 Inhibition of BRD4 with a small-molecule inhibitor known as JQ-1 was highly effective in promoting terminal differentiation of AML LSCs ex vivo and also showed anti-leukemic activity in vivo. 58, 59 JQ-1 was found to be effective against a broad range of AML subtypes and synergizes with FLT3 60 and HDAC 61 inhibitors. The mechanism of action appears to be at least partially due to suppression of MYC expression. 58 Intriguingly, JQ-1 has been shown to inhibit NF-κB activity, which may contribute to its anti-leukemic activity. 62 Since these initial discoveries, several inhibitors of the BET family members have now been developed and some are in early-phase clinical trials.
Inhibition of Anti-apoptotic BCL-2 Family Members
Similar to other malignancies, numerous studies have established that AML cells are dependent on specific anti-apoptotic members of the BCL-2 family for survival. Anti-apoptotic proteins antagonize the activation of pro-apoptotic proteins by binding to their BH3 domains. 63 In particular, MCL-1 and BCL-2 have attracted the most attention as therapeutic targets.
In a series of experiments using lentiviral vectors that inducibly expressed BH3-like ligands to neutralize specific anti-apoptotic BCL-2 proteins, Glaser et al showed that the majority of AML cell lines and some primary AML samples are highly dependent on MCL-1 for survival. 64 Given its importance in promoting AML survival, there has been considerable interest in developing highly specific and potent direct inhibitors of MCL-1. Unfortunately, this approach has proved to be challenging. An alternative approach is to suppress transcription of the MCL-1 gene, which effectively reduces MCL-1 protein levels due to its very short half-life (about 2-4 hours in most cells). 65 Several compounds, including flavopiridol 66 and PIK-75, 67 have been shown to suppress MCL-1 transcription through inhibition of the transcriptional kinases CDK9 and CDK7/9, respectively. PIK-75 treatment was shown to reduce the viability of purified LSCs (CD34
À /CD123 þ ) from primary AML samples ex vivo with minimal toxicity to normal bone marrow CD34þ progenitor cells. Intriguingly, although PIK-75 was identified in a screen based on the ability to suppress MCL-1 levels, it also possesses inhibitory activity against phosphatidylinositol 3-OH kinase, which synergizes with CDK7/9 inhibition to kill AML cells. 67 Numerous studies in the past 20 years have demonstrated dependency on BCL-2 for survival in AML cells. 68, 69 These observations prompted initial attempts to use antisense oligonucleotides to suppress BCL-2 expression in AML patients. Although these clinical trials showed activity in some patients, 70, 71 issues with enzymatic degradation and short half-lives limited its clinical utility. Recent developments in the ABT series of small-molecule inhibitors have revived interest in targeting BCL-2 in AML. ABT-737 was the first molecule discovered in this series and is a highly potent inhibitor of BCL-2, BCL-XL, and BCL-W. 72 ABT-263 was later developed as an orally bioavailable version of ABT-737. 73 Konopleva et al showed that treatment of primary AML samples with ABT-737 ex vivo depleted the LSC population defined as CD34 þ
CD38
À CD123 þ in most but not all cases. 74 More recently, Lagadinou et al demonstrated that ABT-263 is selectively toxic to a subpopulation of AML cells with low levels of reactive oxygen species (ROS), which they found is enriched for LSC activity. 75 The mechanism of action appears to be due to suppression of oxidative phosphorylation (OXPHOS) that occurs with BCL-2 inhibition. This non-canonical role of BCL-2 has previously been reported. 76 The authors found that LSCs, unlike normal HSPCs, are unable to increase glycolysis to compensate for the decrease in OXPHOS, resulting in ATP depletion and ultimately cell death.
Although ABT-263 showed promising preclinical activity, its clinical use has been hampered by thrombocytopenia, which is the major dose-limiting toxicity. 77 This effect is due to the inhibition of BCL-XL, which is required for platelet Abbreviations: LSC, leukemia stem cell; PMID, Pubmed ID; BCL-2, B-cell lymphoma 2; MCL, myeloid cell leukemia 1; PI3K, phosphatidylinositol-3-kinases; XIAP, X-linked inhibitor of apoptosis protein; ROS, reactive oxygen species; GCLC, glutamate -cysteine ligase catalytic subunit; GPX1, glutathione peroxidase 1; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor of kappa light chain enhancer in B cells; Hsp90, heat shock protein 90; IκB, nuclear factor of kappa light chain enhancer in B cells inhibitor; Nrf2, nuclear factor, erythroid 2-like 2; HIF1, hypoxia inducible factor; Wnt, Wingless-related integration site; APL, acute promyelocytic leukemia; STAT, Signal transducer and activator of transcription; FLT3, Fms-like tyrosine kinase 3; ITD, internal tandem duplication; JNK, c-Jun N-terminal kinases; AP1, activator protein 1; MDM2, mouse double minute 2 homolog; Nur, nuclear receptor subfamily; Nor1, neuron-derived orphan receptor 1; TRAIL,TNF-related apoptosis-inducing ligand; MLL, mixed-lineage leukemia; ATRA, all-trans retinoic acid; SIRT1, sirtuin 1; DDIT3, DNA damage-inducible transcript 3; SUMO, small ubiquitin-like modifier; PP2A, protein phosphatase 2A.
survival and function. 78, 79 In response to this limitation, ABT-199 was developed as a highly specific and potent inhibitor of BCL-2 that does not cause thrombocytopenia. 80 ABT-199 has been recently been shown to induce apoptosis in primary human AML blasts and LSCs (defined as CD34
in ex vivo assays. 81 ABT-199 is now in early phase clinical trials for a number of hematologic malignancies, including AML.
We recently found that BCL-2 inhibition selectively targets AML cells with isocitrate dehydrogenase (IDH) mutations through an unbiased large-scale lentiviral RNA interference screen. 82 Importantly, we showed that in vivo treatment of IDH-mutant primary AML with ABT-199 resulted in not only a decrease in bulk disease burden but also a loss of functional LSC activity with minimal hematologic toxicity. This sensitization effect appears to be due to inhibition of cytochrome C oxidase activity in the mitochondrial electron transport chain (ETC) by high intracellular levels of 2-hydroxyglutarate, an oncometabolite that is generated by the mutant enzymes. 83 We further showed that tigecycline, which disrupts ETC function through inhibition of mitochondrial translation, 84 sensitized resistant AML cells to the pro-apoptotic effects of ABT-199. The anti-leukemic activity of other combinations of ETC inhibitors with ABT-199 on the LSC population is under active investigation.
Inhibition of Telomerase Activity
The maintenance of telomeres at the ends of chromosomes through telomerase activity is one of the requirements for unlimited cell divisions in cancer cells. 85 Small-molecule inhibitors of telomerase activity have been shown to restrain the growth of a variety of tumor types. 86 Recently, Bruedigam et al demonstrated that AML LSCs from a retroviral mouse model (MLL-AF9) and primary AML samples are similarly dependent on telomerase activity for survival and proliferation. 87 This effect appears to be dependent on p53 activation as p53 knockdown partially rescued telomerase-deficient LSCs. 87 The authors also identified a telomerase-regulated gene signature that correlated with patient prognosis. Importantly, treatment of xenograft models of human AML with imetelstat, an antisense oligonucleotide that specifically targets the RNA component of the telomerase complex, impaired leukemia progression and delayed relapse following chemotherapy. Important issues to address in future studies include distinguishing between telomere length-dependent and independent mechanisms, investigating potential off-target effects, and identifying synergistic therapeutic combinations.
THE HEMATOPOIETIC NICHE AND ITS INVOLVEMENT IN LEUKEMOGENESIS
The microenvironment for blood forming cells is generally referred to as the hematopoietic niche, 88 and is a complex anatomical site composed of various cell types and structural components regulating stem cell function. Among the supportive cells in the niche are perivascular cells, osteoblasts, osteoclasts, endothelial cells, sympathetic nervous cells, immune cells, adipocytes, and megakaryocytes (for comprehensive review, see Frenette PS, et al, 2014 89 ), some of which are direct descendants of mesenchymal stromal cells (MSCs), an adherent population that can recreate a functional hematopoietic microenvironment upon transplantation to ectopic sites. [90] [91] [92] [93] Whereas it is well known that LSCs prefer to localize within special microenvironments of the bone marrow cavity 94, 95 similar to normal HSCs, it is still unclear whether LSCs require similar microenvironmental support for long-term maintenance of the disease. However, there is growing evidence suggesting that cell-extrinsic signals coming from components of the normal HSC niche have important roles in leukemia pathogenesis. Those key signals mainly influence their survival after chemotherapy 14 and homing to the hematopoietic microenvironments. 96 A permissive microenvironment might also play a role in disease initiation by transforming normal HSCs. 97 Several reports underline the potential contribution of an aberrant hematopoietic microenvironment on leukemogenesis. All of these reports share the common approach of selectively targeting genes in niche-specific cells. Deletion of retinoic acid receptor gamma (RARγ) from the bone marrow microenvironment initiated the formation of a myeloproliferative syndrome, 98 whereas targeted deletion of miRNA-processing endonuclease Dicer1 in Osterixexpressing osteoprogenitors recapitulated key features of myelodysplasia and/or AML. 97 Similarly, a mutation of beta-catenin in osteoblasts resulted in upregulation of Jagged-1, thereby activating the Notch-pathway in hematopoietic cells and leading ultimately to AML development in mice. 99 Furthermore, signals that emanate from neoplastic hematopoietic cells can alter the biology of the niche. Schepers et al showed that neoplastic cells are capable of remodeling the niche into a self-reinforcing leukemic niche. 100 In addition, rather than directly influencing hematopoietic cells and leading to malignant transformation, aberrant niche cells could also simply increase proliferation of HSCs, thereby increasing the potential pool of cells capable of acquiring genetic abnormalities. 101 The growing evidence that (1) signals form the bone marrow microenvironment can drive or select for subsequent transforming events in leukemia stem cells, and (2) signals from leukemia can remodel existing niches to support its growth, implies that such signals may represent candidate targets in novel therapeutic strategies.
TARGETING LSC-NICHE INTERACTIONS
If LSCs depend on specific niche interactions, targeting these interactions might be an effective approach to eradicate the disease. This treatment could either directly influence LSC survival or help sensitize them to conventional cytotoxic agents that are able to get rid of bulk leukemia but usually fail to eliminate LSCs. Most LSCs reside within the chemotherapy-protective endosteal and vascular niches. 95 Dislodging LSCs from their protective microenvironments through systemic administration of granulocyte colony-stimulating factor (G-CSF) could sensitize the cells to chemotherapy and increase long-term therapy success.
14 Other potential targets include blocking the interaction of CXCL12 (SDF-1) on niche cells with CXCR4 expressed on LSCs using CXCR4 inhibitors. This has been shown to increase response rates and decrease leukemia burden in murine leukemia models and led to the initiation of several clinical trials. 102, 103 Combining CXCR4 inhibition with neutralizing antibodies to transforming growth factor-beta has been shown to further increase efficacy. 104 Ligation of the adhesion molecule CD44 on LSCs with monoclonal antibodies and thereby blocking their lodging and trafficking to supportive niches is another promising way proven to be effective in selectively killing AML LSCs. 96 
CONCLUSIONS
Although treatment strategies and corresponding longterm survival for AML patients have not changed drastically over the past three decades, we now are at the frontier of a promising new era of novel targeted therapies that have the potential to specifically attack LSCs without adversely affecting normal hematopoietic stem and progenitor cell populations. One of the biggest future challenges will lie in early and efficient identification of patient and/or leukemia subtype-specific targets within leukemic stem cells that can be tackled in a combinatorial manner using established therapeutics and novel approaches, both biologic and small molecules. Additionally, implementing new modalities that attack interactions with the leukemic stem cell microenvironment are promising strategies that might further improve future leukemia therapy and patient outcomes.
